



Andrew Moeser
416-649-1815
amoeser@litigate.com

January 12, 2021

Lenczner Slaght Welcomes New IP Partner

Canada's leading litigation firm adds Andrew Moeser to its formidable Intellectual Property team.

Andrew Moeser is a versatile and experienced litigator with a passion for intellectual property disputes. Possessing a master's degree in biology and having worked as a coordinator of a phase III clinical trial, Andrew is that combination of litigator and scientist that brings a deep understanding to the complex legal issues facing our clients. He has the expertise clients trust to protect their intellectual property.

"We are delighted to welcome Andrew to our strong and growing IP team," said managing partner Tom Curry. "Andrew brings his wide experience and subject-matter expertise in science, law, and advocacy, to further enhance our ability to meet the demand for our services in solving complex IP legal problems."

Andrew's practice is focused on intellectual property litigation. In patent matters, he has experience with industries such as pharmaceutical and biologics, information technology, and oil and gas. In trademark, copyright, and trade secret matters, Andrew has represented clients in disputes relating to software, gaming, and beauty products. He has also gained experience in commercial litigation relating to environmental contamination, and in regulated industries such as pharmaceuticals and renewable energy.

Andrew has represented clients before all levels of court in Ontario, the Federal Court and Federal Court of Appeal, and the Alberta Court of Appeal. He has also acted *pro hac vice* in proceedings in the United States and has extensive experience as part of international teams litigating large cross-border disputes.

Andrew is also an Adjunct Professor at the University of Toronto Faculty of Law, where he supervises a legal clinic providing assistance to the Structural Genomics Consortium, a not-for-profit public-private partnership that engages in precompetitive basic science research to facilitate and enable the discovery of new medicines.

Welcome, Andrew!

Continue reading:

<https://litigate.com:443/assets/uploads/20210112-093606-2635-The-OR-New-Partner-Ad-AMoeser-Final.pdf>